CELC

Rating buyAI Memo

Celcuity

As of 2026-03-26/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-03-26 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Q4 / Full‑Year 2025 Results — market reaction from 8-K • 2026-03-25

Expected move: -13%

Biggest risk

Regulatory non‑approval, unfavorable label, or disappointing commercial partnering terms would materially compress valuation toward $85 or lower given development‑stage risk and limited near‑term revenue visibility.

Invalidation

Break below $85 or thesis failure.

What would change my mind?

Successful FDA review or a favorable approvable letter plus a commercial/partnering announcement would re-rate Celcuity toward the analyst high (~$155), driven by upside in peak sales assumptions and de‑risked commercialization pathways.

Research note

Recommendation

buy

Confidence

medium

As of

2026-03-26

Base target

$115

p=50%

Bull target

$155

p=25%

Bear target

$85

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Regulatory review following FDA acceptance of NDA — decision window (~12 months)
Successful FDA review or a favorable approvable letter plus a commercial/partnering announcement would re-rate Celcuity toward the analyst high (~$155), driven by upside in peak sales assumptions and de‑risked commercialization pathways.
ANCHOR: {"price": 106.06, "timestamp_utc": "2026-03-26T13:05:34+00:00", "source": "broker_last"} ANALYST_TARGETS_REVIEWED: true Our base target of $115 is set slightly above the analyst median ($111.43) reflecting upside if the NDA review progresses without major delays; the bull target equals the published analyst high (~$155) and the bear reflects downside from regulatory setback.

BearKey bullets

Clinical/regulatory delays during review
Unfavorable FDA decision or CRL
Weak commercial partner economics or launch execution

WatchKey bullets

Q4 / Full‑Year 2025 Results — market reaction from 8-K

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $115 (p=50%)

Bull/Bear spread: +17% / -36%

Vs latest close: Bull +17% · Base -13% · Bear -36%

Scenario probabilities

Bull Target: $155 (p=25%)Base Target: $115 (p=50%)Bear Target: $85 (p=25%)

Commentary

Market tone is cautiously constructive after the recent filings and IR activity: the 8‑K on Mar 25 highlighted reported results [#8-K-2026-03-25], and IR/press materials document an NDA acceptance earlier in Jan 2026 [#PR-undated], producing a mix of positive analyst re‑ratings and guarded positioning. Short‑term headlines (earnings/press) drive volatility while the regulatory review timeline concentrates longer‑term sentiment [#10-K-2026-03-26].

As of 2026-03-26 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Regulatory review following FDA acceptance of NDA — decision window (~12 months)

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-03-26Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$111.43

Range (USD)

$60.00 - $155.00

Count

Query: Celcuity Inc Common (CELC) analyst consensus price target high low average

Celcuity (CELC) Stock Forecast & Price Target
Search result #1
According to projections from 10 analysts, the average 12-month price target for Celcuity is 120.90 USD, with a high estimate of 155 USD and a low estimate ...
Extracted: $120.90, $155.00Open source
CELC / Celcuity Inc. (NasdaqCM) - Forecast, Price Target, ...
Search result #3
The average one-year price target for Celcuity Inc. is $115.26. The forecasts range from a low of $94.94 to a high of $141.75. Read More.
Extracted: $115.26, $94.94, $141.75Open source
CELC Stock Quote Price and Forecast
Search result #4
CELC is trading near the top of its 52-week range and above its 200-day simple moving average. ... The price of CELC shares has increased $8.21 since the market ...
Extracted: $8.21Open source
Celcuity Inc.: Target Price Consensus and Analysts ...
Search result #5
Stock CELC ... Average target price. 120.90USD. Spread / Average Target. +5.85%. High Price Target. 155.00USD. Spread / Highest target. +35.70%. Low Price Target.
Extracted: $120.90, $155.00Open source
Celcuity (CELC) Stock Forecast: Analyst Ratings, Predictions ...
Search result #6
Financial analysts have set a price target of $108.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently ...
Extracted: $108.78Open source
CELC, Celcuity LLC - Stock Analyst Price Targets
Search result #7
Highest price target for CELC is $134, Lowest price target is $94, average price target is $111.43. Most recent stock forecast was given by GIL BLUM from ...
Extracted: $134.00, $94.00, $111.43Open source

Scenarios

Bull Target (Scenario probability)

$155 / p=25% prob

Base Target (Scenario probability)

$115 / p=50% prob

Bear Target (Scenario probability)

$85 / p=25% prob

Price $133 as of 2026-05-29

Nearest Scenario: Base (∆ 13%)

Targets vs latest close: Bull +17% · Base -13% · Bear -36%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-03-25
Q4 / Full‑Year 2025 Results — market reaction from 8-K
Celcuity filed an 8‑K on 2026-03-25 disclosing Results of Operations and Financial Condition (Item 2.02); market reaction and updated guidance/forward commentary from management around this report are a near-term price driver [#8-K-2026-03-25] [#PR-2026-03-18].
Prob 85.00% • Move 8.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Regulatory review following FDA acceptance of NDA — decision window (~12 months)
2027-01-20
Celcuity's investor‑relations materials list a January 2026 press release noting FDA acceptance of a New Drug Application; the ongoing FDA review and any approvable letter or complete response (and related commercial/partnering updates) are a material company‑specific, dated forward driver for share value [#PR-undated] [#10-K-2026-03-26].
Prob 40% • Move 60% • Priced-in 20%

Risks

Clinical/regulatory delays during review
Unfavorable FDA decision or CRL
Weak commercial partner economics or launch execution

Peers

Symbol	Summary
ACAD	Mid‑cap biotech with oncology/Rx focus; useful comparator for commercialization path and regulatory-readout sensitivity.
ALKS	Established specialty pharma with mixed commercial and late‑stage assets; helps frame post‑approval launch and partnership options.
CRNX	Clinical-stage biotech of similar market cap that trades on development‑stage binary readouts and enrollment/regulatory milestones.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Celcuity Inc Common (CELC) analyst consensus price target high low average
Analysis date: 2026-03-26

AI Stock Memo: CELC - Celcuity - RankAlpha